1. Annual Meeting May 24, 2012

2. Competitive Technologies, Inc.  © 2012 2 Statements made about our future expectations are forward- looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K/A for the year ended December 31, 2011, filed with the SEC on May 15, 2012, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward- looking statement. Safe Harbor Statement

3. Competitive Technologies, Inc.  © 2012 3  Funding  Medical Insurance Reimbursement  Sales Growth Topics to be Discussed

4. Competitive Technologies, Inc.  © 2012 4 Basis for Optimism - Calmare Works! Frank Sparadeo, Ph.D.  Doctorate in Clinical Psychology  Private practice since 1983  Worked in hospitals in Massachusetts and Rhode Island  Taught at universities in Massachusetts and Rhode Island  Active in Calmar Pain Relief program since June 2010  Review his study of 250 patients

5. Competitive Technologies, Inc.  © 2012 5 Board Composition Board MemberMember Since Peter Brennan June 2011 Richard D. Hornidge February 2007 Rustin Howard October 2007 Robert G. Moussa January 2012 Stan Yarbro, Ph.D. March 2012

6. Competitive Technologies, Inc.  © 2012 6 Medical Device Corporations vs. CTTC Robert Moussa, CEO - Dilon Technologies 40 Years in Medical Device Industry: Chairman, President & CEO, Dilon Technologies President, Malinkrodt International President & CEO, Malinkrodt Medical Sherwood Medical

7. CTTC Organization Chart Competitive Technologies, Inc.  © 2012 7

8. 8 Funding Types  Government Loan  Two year 6% notes convertible at $1.05/share  Sale of common shares

9. Competitive Technologies, Inc.  © 2012 9 Funding  SBA Loan – One million dollars  Three Investment banking groups  Private Investors

10. Competitive Technologies, Inc.  © 2012 10 Sales Personnel - Domestic Commissioned Sales Staff  Challenges have been: Reimbursement Clinical studies Long lead time for each sale

11. Competitive Technologies, Inc.  © 2012 11 Sales Personnel - Domestic Changes Planned  Hire sales employees  Ability to control time and efforts  Evaluate quality of existing commissioned sales personnel  Increase number commissioned sales personnel

12. Competitive Technologies, Inc.  © 2012 12 International Sales DistributorCountry Able Global Healthcare Sdn BhdMalaysia Biogene Pharma LimitedBangladesh Excel Life Sciences, Inc.India FintradeGreece, Cyprus GEOMC Co. Ltd.Korea, Japan Life Episteme ItaliaItaly, Malta The Mediterranean for Technology & Trading SAL Offshore Lebanon, Turkey, Iraq, Jordan, Oman, Qatar, Bahrain, Kuwait, UAE, Yemen, Saudi Arabia, Mauritania, Morocco, Algeria, Tunisia, Libya, Egypt

13. Competitive Technologies, Inc.  © 2012 13 Insurance Reimbursement  Obtain Medicare Approval Hospital – Outpatient – 1 group Hospital – Inpatient – 10 groups Doctors/Clinics – 10 different groups  Private Carriers Bottom up – work with doctors/clinics on filing claims Top down – work with insurer’s medical directors

14. Competitive Technologies, Inc.  © 2012 14 SUMMARY We have a medical device that is needed. Over 100 million people in the U.S. alone spend over $500 billion on pain. The device works as shown by clinical trials and by Dr. Sparadeo’s research.

15. Competitive Technologies, Inc.  © 2012 15 SUMMARY We have new advisory resources on our Board of Directors. The funding process is in high gear. With funding, we can push sales and insurance reimbursement. The international sales program is in place.

16. Competitive Technologies, Inc.  © 2012 16 SUMMARY Our objectives are as follows:  Move this technology to the forefront of pain therapy  Transform CTTC into a profitable growth company.

17. Competitive Technologies, Inc.  © 2012 17 THANK YOU! Competitive Technologies, Inc. www.competitivetech.net www.calmarett.com